Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes.
10.3803/EnM.2017.32.2.274
- Author:
Eugene HAN
1
;
Gyuri KIM
;
Ji Yeon LEE
;
Yong ho LEE
;
Beom Seok KIM
;
Byung Wan LEE
;
Bong Soo CHA
;
Eun Seok KANG
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
- Publication Type:Original Article
- Keywords:
Atorvastatin calcium;
Rosuvastatin calcium;
Diabetes mellitus;
Renal insufficiency, chronic
- MeSH:
Asian Continental Ancestry Group;
Atherosclerosis;
Atorvastatin Calcium*;
Diabetes Mellitus;
Diabetic Nephropathies;
Dyslipidemias;
Glomerular Filtration Rate;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Logistic Models;
Renal Insufficiency, Chronic;
Rosuvastatin Calcium*
- From:Endocrinology and Metabolism
2017;32(2):274-280
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. METHODS: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a >3% reduction in eGFR in a 1-year period. RESULTS: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m² for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m² for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42). CONCLUSION: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.
